Publication Name	World Journal of Clinical Cases
Manuscript ID	90684
Country	United States

Received	2023-12-11 04:53
Peer-Review Started	2023-12-11 04:53
To Make the First Decision
Return for Revision	2024-01-25 21:30
Revised	2024-01-27 03:45
Second Decision	2024-02-25 02:38
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2024-02-25 07:34
Articles in Press	2024-02-25 07:34
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-03-05 06:40
Publish the Manuscript Online	2024-03-12 06:10

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, General & Internal
Manuscript Type	Editorial
Article Title	Immunoglobulin A glomerulonephropathy: A review
Manuscript Source	Invited Manuscript
All Author List	Mohamad El Labban and Salim Surani
Funding Agency and Grant Number
Corresponding Author	Salim Surani, FCCP, MD, Professor, Department of Medicine & Pharmacology, Texas A&M University, No. 40 Bizzell Street, College Station, TX 77843, United States. srsurani@hotmail.com
Key Words	Immunoglobulin A nephropathy; Glomerulonephritis; Nephritic syndrome; Angiotensin-converting enzyme inhibitor; Angiotensin receptor blocker; Systemic steroids; Mycophenolate mofetil
Core Tip	Immunoglobulin A nephropathy is the most common type of glomerulonephritis globally. The management approach differs based on the level of risk for renal disease progression. In low-risk settings, patients are treated with angiotensin system blockade, while patients with a high risk of progressive renal disease are treated with immunosuppressive therapy. Systemic steroids have been shown to have favorable outcomes when compared to the standard of care in high-risk patients. Unfortunately, steroids are associated with numerous side effects. In some studies, mycophenolate mofetil has been shown to have favorable outcomes when compared to steroids with a better safety profile.
Publish Date	2024-03-12 06:10
Citation	El Labban M, Surani S. Immunoglobulin A glomerulonephropathy: A review. World J Clin Cases 2024; 12(8): 1388-1394
URL	https://www.wjgnet.com/2307-8960/full/v12/i8/1388.htm
DOI	https://dx.doi.org/10.12998/wjcc.v12.i8.1388

Full Article (PDF)	WJCC-12-1388-with-cover.pdf
Manuscript File	90684_Auto_Edited-YJP.docx
Answering Reviewers	90684-Answering reviewers.pdf
Audio Core Tip	90684-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	90684-Conflict-of-interest statement.pdf
Copyright License Agreement	90684-Copyright license agreement.pdf
Peer-review Report	90684-Peer-review(s).pdf
Scientific Misconduct Check	90684-Bing-Lin C-2.png
Scientific Editor Work List	90684-Scientific editor work list.pdf